You are here

Home » Content

A REVIEW ON 2, 4- THIAZOLIDINEDIONE IN TYPE-2 DIABETES

Journal Name:

  • Advance Research in Pharmaceuticals and Biologicals

Publication Year:

  • 2013

Key Words:

Author Name
Abstract (2. Language): 
Diabetes mellitus is associated with impaired glucose metabolism that leads to an increase in blood glucose levels and free radicals production. Type II diabetes affects millions of people in the United States, and its incidence are increasing at an alarming rate. A key underlying feature of type 2 diabetes is insulin resistance, which is associated with characteristic clinical features and increased cardiovascular risk. Thiazolidinediones are well known for reduction in blood glucose level. The thiazolidinediones (TZDs) or 'glitazones' are a new class of oral antidiabetic drugs that improve metabolic control in patients with type 2 diabetes through the improvement of insulin sensitivity. TZDs exert their antidiabetic effects through a mechanism that involves activation of the gamma isoform of the peroxisome proliferatoractivated receptor (PPAR gamma), a nuclear receptor. Several new 2, 4-TZDs such as pioglitazone, rosiglitazone have been marketed for the treatment of type 2 diabetes and in the prevention of its late complications.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon 398102_jatan_et.al_.pdf
  • 2
395-399
  • English

REFERENCES

References: 

1. Igitur-archive.library.uu.nl/dissertations/2006-
0509-200053/c1.pdf
2. S. P. Kushwaha, S. K. Rawat, P. Kumar, A. and K.
Tripathi. Coupling antioxidant and antidiabetic
assets of 2, 4-thiazolidinedione derivatives, Asian J.
Pharm. Ana. Vol. 1: Issue 4, pp. 71-73 (2011).
3. F. Ismail. Current management of type 2 diabetes:
why thiazolidinedione should be the cornerstone of
therapy, The Journal of Applied Research, Vol. 4, No.
3, (2004).
4. P. A. Datar, S. B. Aher. 2DQSAR of novel thiazolidine-
2,4-diones as antihyperglycemic agents, Journal of
Current Pharmaceutical Research 10 (1): 07-14
(2012).
5. http://www.idf.org/types-diabetes
6. Devon Local Pharmaceutical committee Diabetes
Medicines Use Review (MUR) Toolkit.
7. M. C. UNLUSOY, N. D. EVCĐMEN, M. SARIKAYA, O. B.
DUNDAR, R. ERTAN. The inhibitory effects of
thiazolyl-2,4- thiazolidinedione compounds on the
rat kidney aldose reductase enzyme, J. Fac. Pharm,
Ankara. 38 (3): 181-190, (2009).
8. A. Roy, A. S. Bhanwase, T. D. Patil. Synthesis and
evaluation of some novel 5-[4-(substituted)
benzylidene] 2,4thiazolidinediones as oral
antihyperglycemic agents, Research Journal of
Pharmaceutical, Biological and Chemical Sciences.
9. K. Arakawa, T. Ishihara, M. Aoto, M. Inamasu, K.
Kitamura and A. Saito. An antidiabetic
thiazolidinedione induces eccentric cardiac
hypertrophy by cardiac volume overload in rats,
Clinical and Experimental Pharmacology and
Physiology 31: 8–13 (2004).
10. http://www.australianprescriber.com/magazine/2
7/3/67/70#.UXJBm6JTCPs
11. http://journals.prous.comjournalsmf20022408htm
lmf240515imagesVazquez_f1.gif
12. google image/Mechanism of
action/thiazolidinediones
13. National Collaborating Centre for Chronic
Conditions. Type 2 diabetes: national clinical
guideline for management in primary and
secondary care (update), London: Royal College of
Physicians, 2008.
14. A. J. Meechan, C. Henderson, G. Coxon, N. A. Justice,
M. Tettey, H. Grant. Evaluation of the toxicity of a
substituted 2,4-Thiazolidinedione moiety to
isolated rat hepatocytes: Relevance to glitazone
toxicity Proceedings of the British Pharmacological
Society at
http://www.pA2online.org/Vol2Issue4abst138P.ht
ml
15. pharmacy.oregonstate.edu/drug.../reviews/.../dur_r
eview_2003_11_18_t
16. http://en.wikipedia.org/wiki/Thiazolidinedione

Thank you for copying data from http://www.arastirmax.com